Jordan Daily - Dar Al Dawa Development and Investment Company recorded net sales of JD61.15 million in the first nine months of 2026, up 9 per cent from JD56.04 million in the corresponding period of 2025.
Gross profit rose by 19 per cent to JD27.57 million, while net profit increased by 59 per cent to JD4.62 million, according to a disclosure filed with the Amman Stock Exchange on Thursday.
Chairman Akram Jerab, said the results built on the company's performance in previous years and reflected a strategic vision implemented by the executive management despite regional and global challenges.
Jerab commended the efforts of the executive management and staff, reaffirming the board's support for initiatives aimed at sustaining growth and generating value for shareholders.
Chief Executive Officer Khaled Harb, said the 19 per cent increase in gross profit reflected continued improvements in operational efficiency, contributing to the 59 per cent rise in net profit.
Harb added that the company would continue to strengthen its research and production capabilities while expanding strategic partnerships to supply high-quality pharmaceutical products to regional and international markets.
Established in 1975, Dar Al Dawa operates seven manufacturing plants in Jordan and Algeria. The company has also begun construction of a new pharmaceutical factory in Saudi Arabia after obtaining an industrial investment licence.
